A multi-institutional clinical trial showed that a newer technique for collecting prostate biopsy samples reduced the risk of infection compared with traditional biopsy approaches.
The Baltimore-based subsidiary of Japan's Sysmex said that the test is used to identify genetic mutations that are relevant for the treatment of various cancer types.